Clinical Trial Update: Electrophysiological Effects of Irbesartan in Patients With Paroxysmal Atrial Fibrillation (AF) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update examining the electrophysiological effects of irbesartan in patients with paroxysmal atrial fibrillation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Irbesartan (irbesartan)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED